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Identity 
Other names: REPA2, RPA32 
HGNC (Hugo): RPA2 
Location: 1p35.3 
Local order: The human RPA2 gene maps on 1p35.3 
between the SMPDL3B (sphingomyelin 
phosphodiesterase, acid-like 3B) and C1orf38 
(interferon-gamma inducible gene ICB-1 (induced by 
contact to basement membrane)). 
DNA/RNA 
Description 
The RPA2 gene is contained within 24.5 kb of 
chromosome 1.  
The coding sequence is contained within nine exons. 
There is no confirmed alternative splicing of the RPA2 
gene, or differential promoter usage. 
Transcription 
The RPA2 mRNA transcript is 1.5 kb. The RPA2 
promoter contains four E2F consensus sequences 
within the region about 400 bp upstream of the mRNA 
start site, and putative binding sites for ATF-1 and SP-1 
transcription factors. Expression is upregulated 2 to 3-
fold by E2F, with mutation of the three start site-
proximal E2F sites causing a loss of E2F 
responsiveness (Kalma et al., 2001). 
Pseudogene 
RPA2 does not have known pseudogenes. 
 
The sequence numbering corresponds to EMBL locus DQ001128 (26.6 kb). Exon are indicated as boxes (yellow = 5' UTR, blue = CDS, 
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Protein 
 
Upper panel: Schematic showing the key domains of RPA2. 
Lower panel: RPA2 phosphorylation sites are shown in bold, 
with the primary responsible kinases indicated above each site. 
Some sites can be phosphorylated by more than one kinase 
(e.g., T21 by ATM and DNA-PK). 
Description 
RPA2 is the middle subunit of the heterotrimeric 
Replication Protein A (RPA; (reviewed in Binz et al., 
2004)). The subunit is composed of 270 residues, and 
has a nominal molecular weight of 29.2 kDa. RPA2 
contains an N-terminal phosphorylation region with 7 
phosphorylation sites, a central DNA-binding domain 
(termed DBD-D), and a C-terminal region that can 
form a three-helix bundle. One helix of the three helix 
bundle is contributed by each RPA subunit, with this 
structure responsible for supporting heterotrimerization 
of the RPA complex (Bochkareva et al., 2002). At least 
in the non-phosphorylated state, the N-terminal region 
is unstructured. DBD-D is constructed from an 
oligonucleotide/oligosaccharide binding (OB) fold 
(Bochkarev et al., 1999), one of six OB folds found 
with the RPA heterotrimer (four OB folds are located 
in RPA1, and one within RPA3). 
Expression 
RPA is an essential factor for DNA replication and 




General function: RPA is a heterotrimeric single-
stranded DNA (ssDNA) binding protein that is 
essential for chromosomal DNA replication, 
homologous recombination, and particular DNA repair 
reactions (nucleotide excision repair). The apparent 







 (Kim et al., 1992). While RPA2 contains 
a central DBD (Philipova et al., 1996), the major effect 
of mutating DBD-D is to decrease the size of the 
ssDNA occluded by RPA binding, with only minor 
effects on RPA: ssDNA affinity (Bastin-Shanower and 
Brill, 2001). A key function of the RPA2 subunit is to 
regulate RPA activity in DNA replication and repair 
reactions, through the RPA2 phosphorylation state (see 
below). 
1) RPA2 phosphorylation. The N-terminal 33 residues 
of RPA2 contain seven phosphorylation sites. In 
interphase cells, genotoxic stress (e.g., caused by 
chromosomal double-strand DNA breaks or DNA 
replication stress) induces RPA2 phosphorylation by 
members of the phosphatidylinositol 3-kinase-like 
kinase (PIKK; ATM, ATR, and DNA-PK) and cyclin-
dependent kinases (CDK) families (reviewed in Binz et 
al., 2004). Mutation of particular RPA2 
phosphorylation sites causes defects in homologous 
recombination (Lee et al., 2010), and Rad51 
recruitment to nuclear repair foci (Anantha et al., 2008; 
Lee et al., 2010). Mutation of these sites also causes 
genomic instability in response to DNA replication 
stress induced by cellular treatment with hydroxyurea 
(Vassin et al., 2009). RPA phosphorylation also 
increases cell viability in response to DNA damage 
arising during mitosis (Anantha et al., 2008). 
Modification of sites in the phosphorylation region of 
RPA2 proceeds in a favored order in response to 
genotoxic stress (Anantha et al., 2007). The 
phosphorylation of individual RPA2 residues is 
dependent on the type of DNA damage or replication 
stress encountered (Anantha et al., 2007; Vassin et al., 
2009). RPA2 is a substrate both for PP2A and PP4 
phosphatases (Feng et al., 2009; Lee et al., 2010). 
2) Involvement of RPA2 in protein-protein 
interactions. RPA2 interacts with the nucleotide 
excision repair factor XPA (He et al., 1995), base 
excision repair enzyme UNG2 (Mer et al., 2000), 
homologous recombination (HR) factor Rad52 (Mer et 
al., 2000), replication checkpoint protein Tipin (Unsal-
Kacmaz et al., 2007), and the annealing helicase 
HARP/SMARCAL1 (Bansbach et al., 2009; Ciccia et 
al., 2009; Yuan et al., 2009). These interactions likely 
aid the multiple roles of RPA in facilitating DNA 
repair. 
Homology 
A close homolog of RPA2, termed RPA4, is located on 
Xq21.33 (Haring et al., 2010). 
Mutations 
Note 
Naturally-occurring mutations of human RPA2 have 
not yet been described. A small number of genetic 
polymorphisms have been described in SNP datasets 
(Y14S, G15R, and N203S), but these have not yet been 
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Overexpression of the RPA2 (and RPA1) proteins have  
been found to be prognostic indicator of colon cancer. 
Strong associations between RPA2 expression and 
disease stage, lymph node metastasis, and the 
histological grade of carcinomas have been observed. 
Prognosis 
In addition, RPA2 protein expression correlates with 
poor survival of stage II and III patients (Givalos et al., 
2007). 
Ductal breast carcinoma 
Disease 
Levels of anti-RPA2 antibodies was observed to be 
significantly higher in sera from breast cancer patients 
(10.9%; n = 801) as compared to normal controls 
(0.0%; n = 221). Examining individuals with early 
stage intraductal in situ carcinomas, 10.3% (n = 39) 
similarly showed the presence of high levels of anti-
RPA2 antibodies. Even so, follow-up studies indicated 
that there were no apparent differences in mean 
survival, occurrences of a second primary tumor, or 
metastasis frequency between breast cancer patients 
that were positive or negative for anti-RPA2 sera. 
Although RPA is a nuclear protein, RPA was seen to be 
localized to both nuclei and cytoplasm in the cells of at 
least one breast tumor, with RPA also over-expressed 
(Tomkiel et al., 2002). 
Non-small cell carcinoma 
Disease 
A fraction of individuals with squamous cell lung 
cancer were found to have significant levels of anti-
RPA2 antibodies (9.1%; n = 22) (Tomkiel et al., 2002). 
Laryngeal tumors 
Disease 
One patient (out of 35; 2.9%) with head and neck 
tumors tested positive for the presence of anti-RPA2 
sera (Tomkiel et al., 2002). 
Promyelocytic leukemia 
Disease 
A derivative of the human HL-60 promyelocytic 
leukemia cell line (HL-60/P1), selected for its 
decreased sensitivity to undergo apoptosis in response 
to TNF-related apoptosis-inducing ligand (TRAIL), 
was found to have decreased (2-fold) expression of 
RPA2 (Petrak et al., 2009). 
Sjögren syndrome 
Disease 
Serum from a patient with Sjögren syndrome was 
found to have high levels of anti-RPA2 antibodies. A 
higher rate of non-Hodgkin lymphoma, and lymphoid 
malignancies, is seen in individuals with Sjögren 
syndrome, compared to normal individuals (Garcia-
Lozano et al., 1995). 
 
 
Systemic lupus erythematosus (SLE) 
Disease 
One out of 55 individuals with autoimmune disorders 
was found to test positive for anti-RPA2 antibodies 
(1.8%). This individual had SLE, and secondary 
Sjögren syndrome (Garcia-Lozano et al., 1995). 
Rheumatoid arthritis (RA) 
Note 
Fibroblast-like synoviocytes (FLSs) are a cell type 
whose invasive properties provide an indicator of RA 
severity. Microarray studies from FLSs in DA rats 
(arthritis-susceptible inbred model) show a modest 
increase in the level of RPA2 mRNA, compared to 
back-crossed arthritis-resistant DA.F344 (Cia5d) 
congenic strains (Laragione et al., 2008). 
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